Peter C. Farrell, Chairman Emeritus of ResMed Inc . (NYSE:), recently sold 2,000 shares of the company’s common stock. The shares were sold at a price of $248.74 each, amounting to a total transaction value of $497,480. Following this sale, Farrell retains ownership of 83,204 shares. The transaction was conducted under a Rule 10b5-1 plan, which was adopted on May 28, 2024.
In other recent news, ResMed reported an 11% revenue increase and a 27% rise in operating profit in their Q1 Fiscal Year 2025 Earnings Call. This growth was attributed to robust demand for the company’s sleep and respiratory health devices, particularly the AirSense 10 and 11 platforms. ResMed also announced the upcoming launch of the AirTouch N30i mask, expected to boost patient adherence due to its enhanced comfort.
The company is expanding its reach into digital health and adjacent markets, focusing on innovation and strategic acquisitions. ResMed’s revenue reached $1.22 billion, with a gross margin improvement to 59.2% and a 35% increase in net income. A quarterly dividend of $0.53 per share was declared and share buybacks are set to continue.
Despite facing increased competition and supply chain challenges, ResMed remains confident in maintaining its market position. The company’s 2030 strategy aims to empower over 500 million people with its health tech solutions. These are some of the recent developments in the company’s operations.
InvestingPro Insights
While Peter C. Farrell’s recent sale of ResMed Inc. (NYSE:RMD) shares may raise eyebrows, a closer look at the company’s financial metrics and market performance reveals a more nuanced picture. According to InvestingPro data, ResMed boasts a market capitalization of $37.25 billion, reflecting its significant presence in the medical equipment industry.
The company’s stock has shown remarkable strength, with a one-year price total return of 68.61% as of the latest data. This impressive performance is underscored by ResMed’s consistent dividend growth, having raised its dividend for 13 consecutive years, as highlighted by an InvestingPro Tip. This commitment to shareholder returns is further evidenced by a dividend yield of 0.85% and a dividend growth rate of 10.42% over the last twelve months.
ResMed’s financial health appears robust, with revenue growth of 9.88% and an EBITDA growth of 24.39% over the last twelve months. The company’s profitability is also noteworthy, with a gross profit margin of 58.33% and an operating income margin of 30.84% for the same period.
An InvestingPro Tip indicates that ResMed operates with a moderate level of debt, suggesting prudent financial management. This, coupled with the fact that liquid assets exceed short-term obligations, points to a solid financial foundation.
It’s worth noting that ResMed is trading near its 52-week high, with its current price at 97.77% of that peak. While this might raise concerns about valuation, analysts remain optimistic, with seven having revised their earnings upwards for the upcoming period, according to another InvestingPro Tip.
For investors seeking a more comprehensive analysis, InvestingPro offers 16 additional tips on ResMed, providing a deeper understanding of the company’s financial position and market outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
